Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation plc (NASDAQ: PRTA) is described in its own press releases as a late-stage clinical biotechnology company focused on protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. The PRTA news feed on Stock Titan aggregates these company communications, giving investors and observers a single place to follow Prothena’s disclosures and milestones.
In its recent news, Prothena has highlighted progress across a pipeline that includes both wholly-owned and partnered programs. Updates have covered clinical development for Parkinson’s disease through the prasinezumab collaboration with Roche, ATTR amyloidosis with cardiomyopathy via coramitug (formerly PRX004) now being developed by Novo Nordisk, and Alzheimer’s disease programs such as BMS-986446 (formerly PRX005) with Bristol Myers Squibb, PRX012, and the dual Aβ/tau vaccine PRX123. The company has also issued releases on its CYTOPE technology platform, workforce restructuring, and financial results.
Readers of the PRTA news page can review press releases on topics such as Phase 2 and Phase 3 trial plans, Fast Track designations, preclinical data from the TDP-43 CYTOPE program, and corporate actions including an Extraordinary General Meeting to approve a capital reduction to create distributable reserves. Governance and leadership updates, such as changes to the Board of Directors, are also disclosed through these announcements.
By following this curated stream of Prothena’s own news, users can see how the company presents the status of its investigational therapeutics, collaborations with partners like Roche, Novo Nordisk and Bristol Myers Squibb, and its capital and cost structure decisions. The PRTA news page is intended as a convenient starting point for reviewing Prothena’s publicly released information over time.
Prothena Corporation plc (NASDAQ:PRTA) will report its fourth quarter and full year 2020 financial results on February 11, 2021, prior to U.S. market opening. A live audio conference call will follow at 8:30 AM ET, accessible on the Company’s website. Prothena specializes in therapeutics for rare amyloid and neurodegenerative diseases, boasting a pipeline including birtamimab for AL amyloidosis, PRX004 for ATTR amyloidosis, and Alzheimer’s disease programs. The company is collaborating with Roche and Bristol-Myers Squibb on additional treatment candidates.
Prothena Corporation announced significant findings from the VITAL study, highlighting birtamimab's survival benefit in Mayo Stage IV AL amyloidosis patients, achieving a hazard ratio of 0.413 (p=0.025) over 9 months. Following these results, Prothena has entered a Special Protocol Assessment (SPA) agreement with the FDA for a confirmatory Phase 3 study, AFFIRM-AL, set to begin in mid-2021, focusing on all-cause mortality (p<0.10). The total enrollment will target about 150 patients and will assess secondary endpoints related to quality of life.
Prothena Corporation plc (NASDAQ:PRTA) announced positive Phase 1 results for PRX004, an anti-amyloid immunotherapy targeting ATTR amyloidosis. All 7 evaluable patients exhibited a +1.29 point change in Neuropathy Impairment Score (NIS) after 9 months, significantly better than the expected +9.2 points from untreated patients. Three patients reported improvement in neuropathy, with a mean change of –3.33 points. Additionally, cardiac function improved in all evaluable patients. PRX004 demonstrated a favorable safety profile, with no serious adverse events reported.
Prothena Corporation (NASDAQ:PRTA) announced the grant of options to purchase 90,000 ordinary shares to two new employees. The options have an exercise price of $11.00, reflecting the closing price as of December 1, 2020. These options will vest over four years, with 25% vesting after one year and the remaining shares vesting monthly thereafter. This incentive aims to encourage new talent to join Prothena, a company specializing in therapeutics for neurodegenerative diseases and amyloid-related conditions.
Prothena Corporation reported a net loss of $30.6 million for Q3 2020, compared to $19.4 million in Q3 2019. The company has $317.2 million in cash as of September 30, 2020, ensuring funding for ongoing R&D initiatives. Key highlights include the presentation of positive Phase 2 results for prasinezumab in Parkinson's disease, showing a 35% reduction in motor decline, and its advancement into a late-stage study. The company plans to earn a $60 million milestone payment upon dosing the first patient in this study.
Prothena Corporation presents preclinical data on its Alzheimer’s disease portfolio at CTAD 2020, showcasing next-generation anti-Aβ antibodies and a multi-immunogen Aβ-tau vaccine. The anti-Aβ antibodies, designed for subcutaneous administration, exhibit 11-fold greater binding strength to amyloid compared to aducanumab, enhancing patient access. The dual-target vaccine aims to tackle both Aβ and tau pathologies, generating balanced immune responses. Prothena's innovative approaches address significant challenges in patient treatment accessibility and represent a potential step forward in Alzheimer’s therapeutics.
Prothena Corporation plc (NASDAQ:PRTA) will disclose its third quarter and first nine months of 2020 financial results on November 4, after U.S. market close. The company specializes in protein dysregulation and has an extensive pipeline targeting neurodegenerative and rare amyloid diseases. Notably, it collaborates with Roche on prasinezumab for Parkinson’s and with Bristol-Myers Squibb for Alzheimer’s and related conditions. Prothena will not hold a conference call for this earnings release.
Prothena Corporation has announced that its anti-alpha-synuclein antibody, prasinezumab, will progress to a Phase 2b study focusing on patients with early Parkinson's disease, following positive results from the PASADENA study. This trial is set to evaluate efficacy further and is expected to initiate in 2021. Prothena will receive a $60 million milestone payment upon dosing the first patient. The ongoing research aims to address the underlying causes of Parkinson's, impacting a significant number of individuals globally, as current treatments only manage symptoms.
Prothena Corporation (NASDAQ: PRTA) announced the hiring of two new employees, granting stock options to purchase 50,000 shares at an exercise price of $10.31 each. The options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter. This move is part of Prothena’s 2020 Employment Inducement Incentive Plan aimed at attracting talent in the field of neurodegenerative diseases. Prothena focuses on investigational therapeutics for amyloid diseases and has partnered programs targeting various neurological conditions.
Prothena Corporation plc (NASDAQ: PRTA) will hold an investor webcast today at 1:30 PM ET following Roche's presentation of the Phase 2 PASADENA study results at the MDS Virtual Congress 2020. The webcast will review the findings from this study, which focuses on therapeutics for neurodegenerative diseases. Investors can access the presentation via Prothena's website, with a replay available for 90 days. Prothena specializes in developing treatments for conditions such as Parkinson's disease and amyloidosis, leveraging its expertise in protein dysregulation.